The development of EBV-driven B-cell lymphoproliferative disorders following allogeneic haemopoietic stem cell transplantation is a serious and well recognised complication occurring with an incidence of 0.6-26%. 1 Higher incidences occur in the context of T-cell depleted transplants; other risk factors include the use of unrelated and mismatched donors and the use of anti thymocyte globulin (ATG) or anti-CD3 as part of the preparative regimen. In contrast, Campath antibodies (1G or 1H) deplete both T and B cells 2 thus avoiding the selective depletion of T cells. In recent years there has been an increasing number of allografts performed using non-myeloablative or reduced intensity (RIC) conditioning regimens. Early evidence suggests that the increased immunosuppression with RIC allografts may be associated with a high risk of EBV reactivation and post-transplant lymphoproliferate disease (PTLD) especially when they involve ATG administration. In the UK many of these highly immunosuppressive RIC protocols incorporate Alemtuzumab (Campath 1H). The exact dose of Alemtuzumab required for optimal engraftment and immune reconstitution while preventing GVHD and preserving GVL effects is unknown. Hence, several groups including ours have been interested in exploring Alemtuzumab dose reduction and its effect on these parameters. Here, we report an unexpectedly high incidence of PTLD observed following a reduction in Campath total dose from 50 to 30 mg. Details of the three cases of PTLD out of six RIC allografts with reduced dose of Alemtuzumab of 30 mg are given in Table 1 .
The first case was a 62-year-old gentleman who underwent an RIC sibling allograft for MDS-RAEB-1.
At 5 months post transplant he presented with sore throat, blocked sinuses, dysphagia and fever. Within a few days, he became systemically unwell with shortness of breath and hypoxia. CT scanning revealed a large nasopharyngeal mass obstructing his airway and a 5 Â 4 cm inguinal mass, which on biopsy was consistent with PTLD. EBV Q-PCR was 1.4 Â 10 5 copies/ml. His initial response to treatment proved to be transient as shown on FDG-PET scan post treatment (Supplementary Figure 1) . He died from progressive PTLD at 8 months post-transplant.
The second case was a 61-year-old lady with relapsed CLL and 17p deletion who underwent an RIC sibling allograft. At 3 months post allograft she was admitted with persistent pyrexia and shortness of breath. High resolution CT chest scan revealed right mid lobe collapse with right hilar nodes. Bronchoscopy showed abnormal nodularity of the right main bronchus and occlusion of right middle lobe bronchus. Biopsies confirmed CD20-positive lymphoblasts. EBV Q-PCR was 1 Â 10 6 copies/ml confirming the diagnosis of PTLD. She had an excellent response to Rituximab with resolution of symptoms and her EBV PCR came down to o4 Â 10 2 copies/ml. The third case was a 55-year-old gentleman who underwent RIC sibling allograft for CML in second chronic phase. He presented with sore throat and an inflamed left tonsil followed by left cervical lymphadenopathy. Routine reassessment of his disease status at the same time revealed strongly positive BCR-ABL on peripheral blood. Lymph node biopsy was characteristic of PTLD rather than lymphoid blast crisis of CML. EBV qPCR was 2.3 Â 10 3 copies/ml confirming concomitant PTLD. He responded well to Rituximab with complete resolution of lymphadenopathy and EBV qPCR came down to o4 Â 10 2 copies/ ml. He also remains in molecular remission post DLI and Dasatinib treatment. Although the use of non-myeloablative conditioning regimens have reduced early transplant-related mortality, the increased immunosuppression observed may result in profound lymphopenia and an increased risk of viral reactivation. More recently, reports of a higher rate of both EBV reactivation and EBV-related lymphoproliferative disease have been published using such regimens in paediatric patients. 3 In that study, EBV viraemia was shown to be more prevalent following RIC compared to myeloablative transplants (35 vs 8%, Po0.001). Interestingly the increased risk of EBV viraemia and lymphoproliferative disease was significantly associated with the use of ATG pre-transplant rather than Alemtuzumab (35 vs 16.4%, Po0.05). Recent reports have also suggested a high rate of EBV-related complications when ATG is added to non-myeloablative unrelated umbilical cord blood transplant protocols, 4 which further confirms the association between ATG and the risk of EBV-related disease. Unlike ATG, Campath antibodies deplete both T and B cells thus avoiding the selective depletion of T cells which has been shown to be a major factor in increasing the risk of PTLD. 5 Although a reduction in Alemtuzumab dose pre-transplant is desirable to improve immune reconstitution and reduce relapse risk while preserving a low rate of GVHD, it may be that a low dose has sufficient T cell depleting activity but relatively spares the B cells thus allowing EBV-infected B cells to survive and potentially lead to PTLD. Indeed there is some experimental data to suggest that B cells may be less efficiently lysed by Alemtuzumab than T cells. 6 Following the three cases of PTLD occurring in six patients who had a reduction of Alemtuzumab dose to 30 mg in total, the dose of Alemtuzumab was increased back up to 50 mg in total in our centre. No further cases of PTLD have been seen since then, in the following 6 months. Previously, as well, we had observed just one case of PTLD in 204 patients receiving RIC allografts with 50 mg Alemtuzumab.
On the basis of our experience, we suggest that other centres involved in de-escalating dose of Campath should exercise caution when reducing the dose below 50 mg and consider the use of regular PCR-based surveillance of EBV post-transplant. SW Bokhari, E Das-Gupta, NH Russell and J Byrne Clinical Haematology, Nottingham University HospitalsCity Hospital Campus, Nottingham, UK E-mail: syed.bokhari@nuh.nhs.uk
